卵巢上皮性癌组织中CDCA3的表达及其与生存预后的关系  

Expression of CDCA3 in Epithelial Ovarian Cancer and Its Relationship with Survival and Prognosis

作　　者：程其军 刘意 许剑利[1] CHENG Qijun;LIU Yi;XU Jianli(Department of Gynaecology and Obstetrics,Zigong First People's Hospital Zigong Sichuan 643000,China)

机构地区：[1]自贡市第一人民医院妇产科,四川自贡643000 [2]重庆医科大学附属第二人民医院妇产科

出　　处：《联勤军事医学》2023年第1期43-47,共5页Military Medicine of Joint Logistics

基　　金：自贡市卫生健康科研课题项目(20yb015)。

摘　　要：目的探讨卵巢上皮性癌组织中细胞分裂周期相关蛋白3(cell division cycle associated protein 3,CDCA3)的表达与患者生存预后的关系。方法收集2016-06/2019-06月作者医院手术切除的82例患者的卵巢上皮性癌组织,另收集同期40例子宫肌瘤或子宫腺肌病患者手术切除的正常卵巢组织。免疫组织化学染色法检测组织CDCA3表达。随机选取10例患者的卵巢上皮性癌组织和10例患者的正常卵巢组织,采用Western blot检测CDCA3蛋白表达水平。Cox回归分析探讨卵巢上皮性癌生存预后的影响因素,生存分析采用Kaplan-Meier法。结果卵巢上皮性癌组织中CDCA3高表达率高于正常卵巢组织[65.85%(54/82)vs.20.00%(8/40),P<0.05]。卵巢上皮性癌组织CDCA3蛋白相对表达量高于正常卵巢组织(1.32±0.13 vs.0.38±0.08,P<0.05)。病理分级为G3级卵巢上皮性癌患者的CDCA3高表达率高于卵巢上皮性癌G1~G2级患者(P<0.05),病理分期为Ⅲ~Ⅳ期卵巢上皮性癌患者的CDCA3高表达率高于Ⅰ~Ⅱ期患者(P<0.05),淋巴结转移卵巢上皮性癌患者的CDCA3高表达率高于未转移患者(P<0.05),化疗耐药卵巢上皮性癌患者的CDCA3高表达率高于未耐药患者(P<0.05)。Cox回归分析结果显示,病理分级(HR=1.672)、病理分期(HR=1.803)、淋巴结转移(HR=1.325)和CDCA3表达(HR=2.671)是卵巢上皮性癌患者生存预后的影响因素(P<0.05)。CDCA3低表达卵巢上皮性癌患者的中位生存时间高于CDCA3高表达患者(47.50个月vs.21.40个月,P<0.05)。结论卵巢上皮性癌组织CDCA3高表达与不良生存预后有关,可能成为卵巢上皮性癌的生物学标志物。Objective To investigate the relationship between the expression of cell division cycle associated protein 3(CDCA3)in epithelial ovarian cancer and the survival and prognosis of patients.Methods A total of epithelial ovarian cancer tissues surgically removed from 82 patients in author′s hospital from June 2016 to June 2019 were selected,and normal ovarian tissues surgically removed due to uterine leiomyoma or adenomyosis from 40 patients in the same period were selected.The expression of CDCA3 was detected by immunohistochemical staining.Ten cases of epithelial ovarian cancer tissues and ten cases of normal ovarian tissues were randomly selected,and the expression level of CDCA3 protein was detected by Western blot.The factors affecting the survival and prognosis of epithelial ovarian cancer were analyzed by Cox regression.Kaplan Meier method was used for survival analysis.Results The high expression rate of CDCA3 in epithelial ovarian cancer tissues was higher than normal ovarian tissues[65.85%(54/82)vs.20.00%(8/40),P<0.05].The relative expression of CDCA3 protein in epithelial ovarian cancer tissues was higher than normal ovarian tissues(1.32±0.13 vs.0.38±0.08,P<0.05).The high expression rate of CDCA3 in epithelial ovarian cancer patients with pathological grade G3 was higher than that in patients with G1-G2(P<0.05),the high expression rate of CDCA3 in epithelial ovarian cancer patients with pathological stageⅢ-Ⅳwas higher than that in patients with pathological stageⅠ-Ⅱ(P<0.05),the high expression rate of CDCA3 in epithelial ovarian cancer patients with lymph node metastasis was higher than that in patients without metastasis(P<0.05),and the high expression rate of CDCA3 in epithelial ovarian cancer patients with chemotherapeutic resistance was higher than that in patients without chemotherapeutic resistance(P<0.05).The results of Cox regression analysis showed that pathological grade(HR=1.672),pathological stage(HR=1.803),lymph node metastasis(HR=1.325)and CDCA3 expression(HR=2.671)were the factor

关 键 词：卵巢上皮性癌 组织 细胞分裂周期相关蛋白3 预后 

分 类 号：R737.31[医药卫生—肿瘤] R737.33[医药卫生—临床医学]